Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA
Enanta Pharmaceuticals — IDWeek 2022
7 slides from Enanta Pharmaceuticals's conference presentation, Oct 21, 2022
Slide 1: EDP-235 Demonstrates Excellent Penetration into Macrophages and Monocytes
EDP-235, a Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes with the Potential for Mitigation of Cytokine Storm in COVID-19 Patients Yang Li, Indy Zang, Lisha Xu, Daniel Leonard, Khanh Hoang, Tim Greizer, Shucha Zhang, Caroline Kerr, Meng Huang,
Slide 2: EDP-235 is a Potent 3CLpro Inhibitor with Best-in-Class Potential
EDP-235 is a Potent 3CLpro Inhibitor with Potential as a Best-in- Class Antiviral Treatment for SARS-CoV-2 Infection • Novel, oral, directing–acting antiviral specifically designed to target the SARS-CoV-2 protease • Nanomolar potency against emerging SARS-CoV-2 variants (including Delta & Omicron)
Slide 3: Alveolar Macrophages Play an Important Role in SARS-CoV-2 Infection
Alveolar Macrophages (AM) Play an Important Role in SARS- CoV-2 Infection • Macrophages, including lung AM, and monocytes are the first line of defense against SARS- CoV-2. • Several reports have suggested that SARS-CoV-2 can hijack AM and monocytes for replication and viral spread, which may, in tu
Slide 4: EDP-235: Excellent Penetration into Alveolar Macrophages in Rats
EDP-235: Excellent Penetration into Alveolar Macrophages(AM) in Rats Plasma AM AUC Ratio Compd. Cmax AUC0- Cmax AUC0- over Plasma (μg/mL) (μg-h/mL) (μg/mL) (μg-h/mL) EDP-235 1.2 9.6 50.7 272.0 28.4 nirmatrelvir 1.5 2.7 0.5 1.3 0.5 50 EDP-235 50 nirmatrelvir EDP-235 (µg/ml) PLASMA AM PLASMA AM nirm
Slide 5: EDP-235: Superior Ex Vivo Intracellular Uptake into Target Cells
EDP-235: Superior Ex Vivo Intracellular Uptake into Target Cells Extracellular Ratios 40 EDP-235 Nirmatrelvir Intracellular / 30 20 10 0 Lung Epithelial Kidney Epithelial Monocyte Macrophage Intracellular / Extracellular Ratios in Human Cell Lines Compound Lung Epithelial Kidney Epithelial Monocyte
Slide 6: Conclusions
Conclusions • EDP-235, a novel and potent SARS-CoV-2 3CL protease inhibitor, demonstrated excellent penetration into monocytes and macrophages, including lung alveolar macrophages. • EDP-235 has the potential to eliminate SARS-CoV-2 replication in sentinel immune cells, thus potentially mitigating m
Slide 7: Acknowledgements
Acknowledgements Enanta Pharmaceuticals, Inc.’s SARS-CoV-2 Team: • Senior Vice President & Chief Scientific Officer: Y. S. Or • DMPK • In Vivo Pharmacology • Chemistry • Toxicology • Y. Li • K. Hoang • R.C. Shen • G. Hoover • T.Z. Zang • S. L. Chan • X.C. Xin • B. Yamamoto • L. Xu • T. Greizer • W.